Comparative efficacy and safety of vedolizumab and antitumor necrosis factor alfa in patients with inflammatory bowel diseases: A meta‑analysis

.blurhash-client-img { display: none !important; }

Open Access

|Apr 2025

Authors

Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China

Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China

Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China

Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China

Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China

DOI: https://doi.org/10.2478/acph-2025-0004 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075

Language: English

Page range: 23 - 40

Accepted on: Jan 20, 2025

Published on: Apr 10, 2025

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

Related subjects:

© 2025 Yafang Li, Jin Ding, Chong Lu, Yiping Hong, Qunying Wang, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.